HIRA to designate hospitals for Soliris

Published: 2012-06-04 06:57:00

Updated: 2012-06-04 06:57:00

From August 1, the national health insurance will cover Soliris (eculizumab) as a treatment for patients in Korea with paroxysmal nocturnal hemoglobinuria (PNH), the Health Insurance Review and Assessment Service said Thursday.

PNH is an ultra-rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis.

The HIRA said that considering ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.